Progress and prospects: gene therapy for mitochondrial DNA disease

Area of Science:

• Mitochondrial genetics
• Molecular biology
• Genetic therapy

Background:

• Mitochondrial genome defects cause diverse clinical disorders with limited treatment options.
• Current treatments are mainly surgical or transplant-based, necessitating novel therapeutic strategies.
• Genetic therapies are being developed due to the lack of effective treatments for mitochondrial diseases.

Purpose of the Study:

• To review emerging genetic-based therapeutic approaches for mitochondrial DNA (mtDNA) disorders.
• To explore strategies for engineering mitochondrial genes and targeting pathogenic mtDNA mutations.
• To discuss methods for shifting heteroplasmy levels towards normal mtDNA.

Main Methods:

• Allotopic expression: Engineering mitochondrial genes for expression in the nucleus.
• Xenotopic expression: Utilizing single-subunit enzymes from other species to bypass complex defects.
• Nuclear transfection: Introducing genes encoding restriction enzymes or zinc finger proteins to target mtDNA mutations.

Main Results:

• Allotopic and xenotopic expression show promise in cultured cells for circumventing mitochondrial defects.
• Nuclear transfection successfully targets pathogenic mtDNA mutations, including in heteroplasmic cells.
• Various invasive and non-invasive methods are being developed to manage heteroplasmy levels.

Conclusions:

• Genetic engineering approaches like allotopic and xenotopic expression offer potential therapeutic avenues for mitochondrial disorders.
• Targeting mtDNA mutations and managing heteroplasmy are key goals for developing effective genetic therapies.
• While still experimental, these strategies represent significant progress towards treating mitochondrial diseases.